Literature DB >> 29966473

Metabolic behavior and prognostic value of early and end of treatment 18F-FDG PET/CT in adult Burkitt's lymphoma: the role of Deauville and IHP criteria.

Domenico Albano1, Giovanni Bosio1, Alessandro Re2, Chiara Pagani2, Raffaele Giubbini3, Francesco Bertagna3.   

Abstract

Burkitt's lymphoma is a lymphoma with unclear metabolic behavior at 18F-FDG-PET/CT and no validated criteria in treatment evaluation and prediction of outcome exist. Sixty-five patients were retrospectively included: all underwent baseline 18F-FDG-PET/CT, 56 interim PET/CT (iPET/CT) and 54 end of treatment PET/CT (eotPET/CT) after chemotherapy. Interim and eotPET/CT results were visually interpreted according to the criteria of the IHP and Deauville-five-point-scale. Results were correlated with PFS and OS to assess and to compare the predictive value of iPET and eotPET according to each criterion. All baseline PET/CT showed increased 18F-FDG uptake in nodal and extranodal lesions. The median PFS and OS were 44.6 and 48.2 months with 3-year and 5-year PFS of 76% and 62% and 3-year and 5-year OS of 71% and 57%, respectively. EotPET/CT results using DC and IHP significantly correlate with OS and PFS; while iPET/CT did not correlated with OS and PFS.

Entities:  

Keywords:  Burkitt’s lymphoma; Deauville criteria; International Harmonization Project; PET/CT

Mesh:

Substances:

Year:  2018        PMID: 29966473     DOI: 10.1080/10428194.2018.1482541

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma.

Authors:  Domenico Albano; Giovanni Bosio; Chiara Pagani; Alessandro Re; Alessandra Tucci; Raffaele Giubbini; Francesco Bertagna
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-02       Impact factor: 9.236

2.  18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the diagnosis and follow-up of primary hepatic diffuse large B-cell Lymphoma: A clinical case report.

Authors:  Li Wang; Ping Dong; Weiming Hu; Bole Tian
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

3.  The Clinical Accuracy and Risk Stratification in End of Therapy 18F-FDG PET/CT in Burkitt Lymphoma.

Authors:  Yi Wen Mo; Zi Zheng Xiao; Yuan Wei; Xin Ling Li; Xu Zhang; Wei Fan
Journal:  Front Oncol       Date:  2021-04-21       Impact factor: 6.244

Review 4.  RESISTing the Need to Quantify: Putting Qualitative FDG-PET/CT Tumor Response Assessment Criteria into Daily Practice.

Authors:  J G Peacock; C T Christensen; K P Banks
Journal:  AJNR Am J Neuroradiol       Date:  2019-11-28       Impact factor: 4.966

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.